Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-207266 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo |
| Arm 2 | PLACEBO_COMPARATOR | Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo |
| Name | Type | Description |
|---|---|---|
| SB-207266 | DRUG | White, oval, biconvex tablets containing either 10mg, 25mg or 40mg |
| Placebo | OTHER | Placebo to match SB-207266 |
Inclusion Criteria: * Symptomatic persistent atrial fibrillation requiring DC cardioversion. * Duration of AF \>48 hrs. \<6 months Exclusion Criteria: * Concomitant Class I and/or III anti-arrhythmic drugs. * Amiodarone treatment within 3 months of the study. * Other inclusion or exclusion criter...
SB-207266 is an investigational small molecule being studied for the prevention of recurrence of atrial fibrillation. It is intended for patients with atrial fibrillation, a condition characterized by an irregular and often rapid heart rate. The drug is currently in clinical development and has not been approved by regulatory authorities.
SB-207266 is a small molecule developed by GSK plc. Its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential to prevent recurrence of atrial fibrillation, but the precise mechanism of action is not publicly detailed.
SB-207266 is being developed by GSK plc, a global pharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with atrial fibrillation.
SB-207266 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study involving 520 participants. The drug remains investigational and has not received regulatory approval for any indication.
SB-207266 has been evaluated in one completed Phase 2 clinical trial with the identifier NCT00041496, titled 'Prevention Of Recurrence Of Atrial Fibrillation.' The trial enrolled 520 participants aged 18 years and older, and it was randomized, double-blind, and placebo-controlled. The study has been completed.
SB-207266 is not known to have alternative names. It is a unique investigational compound developed by GSK plc for the prevention of atrial fibrillation recurrence. No other names or aliases have been associated with this drug in available information.